Capricor Therapeutics Company Profile (OTCMKTS:CAPR)

About Capricor Therapeutics (OTCMKTS:CAPR)

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CAPR
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $17.55 million
  • Outstanding Shares: 21,399,000
Average Prices:
  • 50 Day Moving Avg: $2.42
  • 200 Day Moving Avg: $2.71
  • 52 Week Range: $0.72 - $5.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.99
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4 million
  • Price / Sales: 4.39
  • Book Value: ($0.19) per share
  • Price / Book: -4.32
Profitability:
  • EBIDTA: ($16,850,000.00)
Misc:
  • Average Volume: 190,723 shs.
  • Short Ratio: 1.56
 

Frequently Asked Questions for Capricor Therapeutics (OTCMKTS:CAPR)

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the OTCMKTS under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (OTCMKTS:CAPR) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The business earned $0.88 million during the quarter, compared to analysts' expectations of $0.87 million. View Capricor Therapeutics' Earnings History.

Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2017?

3 brokers have issued 12 month target prices for Capricor Therapeutics' stock. Their forecasts range from $12.00 to $14.00. On average, they anticipate Capricor Therapeutics' stock price to reach $13.33 in the next year. View Analyst Ratings for Capricor Therapeutics.

Who are some of Capricor Therapeutics' key competitors?

Who owns Capricor Therapeutics stock?

Capricor Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (1.11%), LLBH Private Wealth Management LLC (0.68%), Vanguard Group Inc. (0.00%), Granite Point Capital Management L.P. (0.00%), Goldman Sachs Group Inc. (0.27%) and Geode Capital Management LLC (0.00%). Company insiders that own Capricor Therapeutics stock include Anthony Bergmann, Eduardo Marban, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.

Who sold Capricor Therapeutics stock? Who is selling Capricor Therapeutics stock?

Capricor Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC, Goldman Sachs Group Inc. and Granite Point Capital Management L.P.. View Insider Buying and Selling for Capricor Therapeutics.

Who bought Capricor Therapeutics stock? Who is buying Capricor Therapeutics stock?

Capricor Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Capricor Therapeutics stock in the last two years include Anthony Bergmann, Eduardo Marban, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Insider Buying and Selling for Capricor Therapeutics.

How do I buy Capricor Therapeutics stock?

Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Capricor Therapeutics stock cost?

One share of Capricor Therapeutics stock can currently be purchased for approximately $0.82.

Analyst Ratings

Consensus Ratings for Capricor Therapeutics (OTCMKTS:CAPR) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.33

Analysts' Ratings History for Capricor Therapeutics (OTCMKTS:CAPR)
Show:
DateFirmActionRatingPrice TargetDetails
3/16/2017HC WainwrightSet Price TargetBuy$14.00View Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$14.00View Rating Details
10/20/2016Roth CapitalSet Price TargetBuy$12.00View Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)
Earnings by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Earnings History by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.15)($0.17)$0.87 million$0.88 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.30)($0.14)$1.05 million$0.91 millionViewN/AView Earnings Details
11/10/2016Q316($0.27)($0.29)$1.12 million$0.75 millionViewN/AView Earnings Details
8/15/2016Q2($0.24)($0.26)$1.22 million$1.13 millionViewListenView Earnings Details
5/12/2016Q116($0.19)($0.26)$1.10 million$1.22 millionViewListenView Earnings Details
3/17/2016Q415($0.19)($0.21)$1.10 million$1.12 millionViewN/AView Earnings Details
11/12/2015Q315($0.26)($0.18)$1.10 million$1.32 millionViewN/AView Earnings Details
8/13/2015Q215($0.26)($0.19)$1.10 million$1.29 millionViewN/AView Earnings Details
5/12/2015Q1 2015($0.14)($0.23)$1.10 million$1.79 millionViewN/AView Earnings Details
3/18/2015Q4 2014($0.14)($0.16)$1.30 million$1.40 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.22)($0.13)$1.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Capricor Therapeutics (OTCMKTS:CAPR)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.83 EPS

Dividends

Dividend History for Capricor Therapeutics (OTCMKTS:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Capricor Therapeutics (OTCMKTS:CAPR)
Insider Trades by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Institutional Ownership by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Insider Trades by Quarter for Capricor Therapeutics (OTCMKTS:CAPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/9/2017Louis ManzoDirectorBuy10,000$3.10$31,000.00View SEC Filing  
5/9/2017Sinai Medical Center CedarsMajor ShareholderBuy1,145,161$3.10$3,549,999.10View SEC Filing  
9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.00View SEC Filing  
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.00View SEC Filing  
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.00View SEC Filing  
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.00View SEC Filing  
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.40View SEC Filing  
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.00View SEC Filing  
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.00View SEC Filing  
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Capricor Therapeutics (OTCMKTS:CAPR)
Latest Headlines for Capricor Therapeutics (OTCMKTS:CAPR)
Source:
DateHeadline
finance.yahoo.com logoCapricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board
finance.yahoo.com - May 25 at 5:32 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 6:58 PM
finance.yahoo.com logoCapricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 16 at 11:17 AM
finance.yahoo.com logoCapricor reports 1Q loss
finance.yahoo.com - May 16 at 11:17 AM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Posts Earnings Results
www.americanbankingnews.com - May 16 at 10:32 AM
finance.yahoo.com logoInvestor Network: Capricor Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 3:48 PM
rttnews.com logoCapricor Therapeutics Inc. (CAPR) Plunged To A New Low On Study Results
www.rttnews.com - May 15 at 11:28 AM
reuters.com logoBRIEF-Capricor Therapeutics provides update on ALLSTAR trial
www.reuters.com - May 12 at 4:42 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Says ALLSTAR Phase II Trial of CAP-1002 Showed Low Probability of Achieving Statistically-Significant Difference
www.streetinsider.com - May 12 at 4:42 PM
nasdaq.com logoMid-Day Market Update: Trade Desk Rises After Q1 Results; Capricor Therapeutics Shares Slide
www.nasdaq.com - May 12 at 4:42 PM
finance.yahoo.com logoCapricor Therapeutics Provides Update on ALLSTAR Trial
finance.yahoo.com - May 12 at 4:42 PM
americanbankingnews.com logoInsider Buying: Capricor Therapeutics Inc (CAPR) Major Shareholder Buys 1,145,161 Shares of Stock
www.americanbankingnews.com - May 11 at 10:14 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Director Louis Manzo Buys 10,000 Shares
www.americanbankingnews.com - May 11 at 4:28 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Announces $3.7M Private Placement of Common Stock
www.streetinsider.com - May 8 at 10:10 AM
reuters.com logoBRIEF-Capricor Therapeutics reports private placement of common stock
www.reuters.com - May 8 at 10:10 AM
finance.yahoo.com logoCapricor Therapeutics Announces Private Placement of Common Stock
finance.yahoo.com - May 8 at 10:10 AM
finance.yahoo.com logoCapricor Therapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on Monday, May 15
finance.yahoo.com - May 4 at 4:18 PM
americanbankingnews.com logoCapricor Therapeutics (CAPR) Receiving Positive Press Coverage, Study Shows
www.americanbankingnews.com - May 3 at 4:20 PM
americanbankingnews.com logoCapricor Therapeutics (CAPR) Earns Daily Media Impact Rating of 0.19
www.americanbankingnews.com - April 26 at 10:16 PM
rttnews.com logoCapricor Reports Positive 6-month Results From Duchenne Muscular Dystrophy Trial
www.rttnews.com - April 26 at 8:00 PM
seekingalpha.com logoCapricor Therapeutics (CAPR) to Discuss Top-Line Six-Month Results of the HOPE-Duchenne Trial - Slideshow
seekingalpha.com - April 26 at 8:00 PM
finance.yahoo.com logoCapricor Therapeutics to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day
finance.yahoo.com - April 26 at 2:59 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Announces Positive Six-Month Results from Randomized Phase I/II HOPE Clinical Trial in DMD
www.streetinsider.com - April 25 at 3:59 PM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 3:59 PM
reuters.com logoBRIEF-Capricor Therapeutics announces positive six-month results from randomized phase I/II hope clinical trial
www.reuters.com - April 25 at 12:22 PM
finance.yahoo.com logoCapricor Therapeutics to Report Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
finance.yahoo.com - April 25 at 12:22 PM
finance.yahoo.com logoCapricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
finance.yahoo.com - April 25 at 12:22 PM
finance.yahoo.com logoCapricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results
finance.yahoo.com - April 25 at 12:22 PM
americanbankingnews.com logoCapricor Therapeutics (CAPR) Earns Daily Coverage Optimism Rating of 0.57
www.americanbankingnews.com - April 20 at 10:28 AM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 17 at 5:56 PM
finance.yahoo.com logoPipeline of Duchenne Muscular Dystrophy Market Review Research Covering 21 Major Companies for H1 2017 at ReportsnReports.com
finance.yahoo.com - April 7 at 8:48 AM
finance.yahoo.com logoETFs with exposure to Capricor Therapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:48 AM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - March 31 at 9:21 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Given a $14.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 22 at 7:44 AM
capitalcube.com logoCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
us.rd.yahoo.com - March 21 at 4:28 PM
capitalcube.com logoCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
us.rd.yahoo.com - March 21 at 4:28 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:27 PM
americanbankingnews.com logoCapricor Therapeutics Inc (CAPR) Announces Quarterly Earnings Results, Beats Expectations By $0.16 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
reuters.com logoBRIEF-Capricor Therapeutics q4 loss per share $0.21
www.reuters.com - March 15 at 9:29 PM
biz.yahoo.com logoQ4 2016 Capricor Therapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - March 15 at 4:28 PM
finance.yahoo.com logoCapricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - March 15 at 4:28 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - March 15 at 4:28 PM
finance.yahoo.com logoCapricor reports 4Q loss
finance.yahoo.com - March 15 at 4:28 PM
finance.yahoo.com logoInvestor Network Invites You to the Capricor Therapeutics Fourth Quarter and Full Year 2016 Business Update and Financial Results Conference Call and Webcast on Wednesday, March 15, 2017
finance.yahoo.com - March 14 at 9:03 PM
seekingalpha.com logoCapricor Therapeutics (CAPR) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 4:52 PM
prnewswire.com logoCapricor Therapeutics to Hold Fourth Quarter and Full Year 2016 Financial Results and Corporate Update Conference ... - PR Newswire (press release)
www.prnewswire.com - March 7 at 12:35 PM
finance.yahoo.com logoCapricor Therapeutics to Hold Fourth Quarter and Full Year 2016 Financial Results and Corporate Update Conference Call on Wednesday, March 15
finance.yahoo.com - March 7 at 12:35 PM
prnewswire.com logoCapricor Therapeutics to Present at Two Investor Conferences in March - PR Newswire (press release)
www.prnewswire.com - February 23 at 9:07 PM
finance.yahoo.com logoCapricor Therapeutics to Present at Two Investor Conferences in March
finance.yahoo.com - February 23 at 4:06 PM
investopedia.com logoCapricor Ends Cenderitide Heart Drug Program (CAPR)
www.investopedia.com - February 18 at 10:08 AM

Social

Chart

Capricor Therapeutics (CAPR) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff